PFE - Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
COVID-19 Pandemic
BioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's (AZN) COVID-19 vaccine in China. The candidate is an adenovirus vector-based COVID-19 vaccine that was created by Oxford University and partnered by AstraZeneca. Financial details of the China deal were not disclosed, but BioKangtai did promise to make at least 100 million doses of the vaccine by the end of 2020 and 200 million doses per year by the end of 2021.
Shanghai Fosun Pharma (SHA: 600196; HK; 02196) reported it has dosed the first 72 participants in